Antitumor effects of Endostar (rh-endostatin) combined with gemcitabine in different administration sequences to treat Lewis lung carcinoma

This article was published in the following Dove Press journal: Cancer Management and Research

Yuan Li1,*
Pan Huang2,*
Hongju Peng1
Hongcheng Yue1
Min Wu1
Shanshan Liu1
Rongsheng Qin1
Juan Fan1
Yunwei Han1

1The Oncology Department, Affiliated Hospital of Southwest Medical University, Lu Zhou, Sichuan 646000, People’s Republic of China; 2Neurology Department, Deyang People’s Hospital, Deyang, Sichuan 618000, People’s Republic of China

*These authors contributed equally to this work

Background: Endostatin therapy is known to efficiently inhibit angiogenesis and growth of endothelial cells. Nonetheless, the antitumor mechanisms of endostatin combined with chemotherapy remain to be elucidated.

Methods: In our study, a Lewis lung carcinoma transplant mouse model was established and treated with the recombinant human [rh]-endostatin, Endostar, combined with gemcitabine at different sequences. 18F-FDG PET/CT imaging was performed to monitor tumor growth, and hypoxia was examined using an oxygen microelectrode. Vascular endothelial growth factor (VEGF) and alpha smooth muscle actin (α-SMA) levels were detected via immunohistochemistry analysis and cell cycle distributions were analyzed by flow cytometry.

Results: Endostar decreased VEGF expression, improved hypoxia, and influenced cell cycle distributions. Simultaneous treatment of Endostar and gemcitabine displayed significantly tumor inhibition, possessed the lowest uptake of FDG, improved oxygen partial pressure, decreased expression of VEGF, and increased pericyte coverage. Cell cycle analysis demonstrated that cells accumulated in the S phase following gemcitabine treatment and G0/G1 arrest occurred following Endostar treatment. An increase of cells in G0/G1 phase was observed following treatment with Endostar and gemcitabine.

Conclusions: Our study suggests that the combination therapy of Endostar with gemcitabine simultaneously may optimally enhance their individual antitumor effects.

Keywords: recombinant human endostatin, gemcitabine, antiangiogenic, combination therapy

Introduction
Lung cancer is a major cause for morbidity and mortality worldwide.1 Non-small cell lung cancer (NSCLC) constitutes 80% of lung cancer cases in China, and chemotherapy plays a major role in the treatment of advanced NSCLC.2,3 Gemcitabine (GEM) is a cell cycle specific anticancer agent and is administered along with platinum to treat NSCLC.4 However, the therapeutic effect of gemcitabine is limited due to strong side effects and development of drug resistance.

The growth and metastasis of tumors depend on neovascularization, which is controlled by both angiogenic and anti-angiogenic factors. Particularly, when solid tumors reach a diameter beyond 2 mm, cancer cells begin to secrete pro-angiogenic factors, which in turn secure tumor growth and development. Currently, several
molecules are known to promote angiogenesis in tumors, including vascular endothelial growth factor-A (VEGF-A), placental growth factor (PGF), and basic fibroblast growth factor (bFGF), and the new blood vessels supply oxygen and nutrients to the tumor. Tumor growth, therefore, can be achieved by blocking these angiogenic molecules. Thus, angiogenic inhibitors have served as successful cancer treatments in subsets of cancer patients, and more clinical trials are on the way to increase the repertoire of angiogenic inhibitors available for cancer treatment.

Endostatin is a 20-KDa C-terminal fragment originated from Collagen XVIII, and has the broadest anti-cancer spectrum among endogenous angiogenesis inhibitors. Importantly, more than 12% of the angiogenic regulatory genes found in the human genome are regulated by endostatin. Although the molecular mechanisms regulating endostatins remain unclear, various line of research suggest that endostatins can block cell responses to angiogenesis molecules, such as VEGF and FGF, which in turn inhibits vascular endothelial proliferation and migration. Given that endostatins have been shown to lack efficacy, a novel human recombinant (rh) version of endostatin that is expressed in Escherichia coli called Endostar (rh-endostatin) was approved by the United States Federal Drug Administration (FDA) in 2005 for treatment of NSCLC. Notably, compared with endostatin, the stability and biological activity of Endostar was greatly enhanced.

The structure and function of the tumor vasculature is abnormal in nature, resulting in a hypoxic tumor microenvironment with high permeability. Despite the traditional views on antiangiogenesis, Jain et al found that antiangiogenic therapy can decrease tumor blood vessel density and augment pericyte coverage, inducing tumor vasculature structure to normalize vascular function. Additionally, these vasculature changes can reduce tumor blood vessel leakiness, thereby improving the tumor’s hypoxic environment. During this tumor developmental period, anticancer treatments can be more effective when used in combination with radiotherapy or chemotherapy modalities. Previous studies have suggested that endostatin alone is not effective in suppressing tumor growth and metastasis unless combined with chemotherapy. For instance, Zhu et al found that esophageal squamous carcinoma could be inhibited more effectively when Endostar was used in combination with radiotherapy. Moreover, Ren et al showed that Endostar had an additive effect with cyclophosphamide (CTX) and cisplatin in tumors derived from the B16-F10 melanoma cell line or the A549 NSCLC cell line. Nevertheless, the process of tumor vasculature normalization is transient and due to the complexity underlying the mechanisms regulating angiogenesis, the most effective administration schedule for the combined treatment using endostar and chemotherapy is unclear; therefore, the best administration schedule of endostar is important for improving treatment regimes for NSCLC. The present study worked towards defining an optimal combination treatment using Endostar in combination with gemcitabine in a murine Lewis lung carcinoma (LLC) xenograft cancer model.

**Materials and methods**

**Mice, reagents, and cell lines**

C57BL/6 female mice, 6–8 weeks old, were purchased from Tengxin Biotechnology Co. (Chongqing, China) and housed at 25–29 °C, 50–76% humidity at a 12/12 light/dark cycle. All experiments involving animals were reviewed and approved by the Institutional Animal Care and Treatment Committee of the Southwest Medical University, Sichuan, China. And all animal experiments were performed according to the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978).

LLC cell line used in our experiment were purchased by the Experimental Research Center of the Affiliated Hospital of Southwest Medical University (Luzhou, China) from the Cell Bank of the Chinese Academy of Sciences and maintained in PPMI-1640 cell culture media.

About 1×10^6 of LLC cells in 0.1 ml of phosphate-buffered saline (PBS) were injected subcutaneously (SC) into the right proximal hind leg of C57BL/6 mice.

The human recombinant endostatin, Endostar (rh-ES), was kindly provided by Shandong Simcere Medgenn Biopharmaceutical Co. (Yantai, Shandong, China) and stored at 4 °C. Endostar was then dissolved in 0.2 ml of 0.9% normal saline (NS) and administrated to each animal at a dose of 10 mg/kg/day by intraperitoneal (IP) injection.

Gemcitabine was purchased from Haosen Pharmaceutical Co. (Jiangsu, China). According to previous studies, gemcitabine was dissolved in 0.2 ml 0.9% NS and administrated to each animal at a dose of 30 mg/kg by IP injection.

**Treatment groups**

10 days after LLC inoculation, tumor-bearing mice were randomly divided into control group, Endostar (ES) alone, gemcitabine (GEM) alone, Endostar first (ES/GEM),
gemcitabine first (GEM/ES), Endostar and gemcitabine simultaneously (ES + GEM) group (n=12, per group) [Figure 1]. In brief, i) control group (negative control) was left untreated; ii) ES alone (10 mg/kg/d for 14 days); iii) GEM alone (30 mg/kg/day administered on day 1 and 8); iv) ES/GEM (Endostar administered on days 1–14, and gemcitabine administered on days 5 and 12); v) GEM/ES (Endostar administered on days 2–15, and gemcitabine administered on days 1 and 8); vi) ES + GEM (Endostar administered on days 1–14, and gemcitabine administered on days 1 and 8). Tumor volume was measured every two days by caliper and the tumor volume was calculated according to the following formula: \( V = \frac{1}{2}a b^2 \) (where \( V \) is the tumor volume, \( a \) is the length of the major axis, and \( b \) is the length of the minor axis). The mice were sacrificed after the treatment ended.

**Flow cytometry analysis**

Tumor tissue was dissected and prepared into a single cell suspension. The single cell suspension was fixed in 70% cold ethanol for 12–24 hrs. Next, the suspension was precipitated by centrifugation at 1,000 r/min for 1 min. The cell was rinsed once in PBS (pH 7.4) for 2–3 mins and centrifuged at 2,000 r/min for 3–4 mins. Then the sample was stained with propidium iodide (PI) for cell cycle analysis.

**Immunohistochemistry**

Tumor tissues were fixed in 10% neutral formaldehyde, embedded in paraffin and cut into 3 \( \mu \)m sections. Then, the sections were stained with the hematoxylin and eosin (H&E) dye. Subsequently, the sections were treated with specific antibodies for analysis. Briefly, the sections were stained with rabbit anti-mouse VEGF or alpha-smooth muscle actin (\( \alpha \)-SMA) primary antibodies and incubated with horseradish peroxidase (HRP)-conjugated goat anti-mouse secondary antibodies. Next, the slides were visualized by incubation with diaminobenzidine (DAB) and counter-stained with hematoxylin.

For VEGF expression analysis, we calculated as follows: five areas were selected randomly from each of the slides generated from the 6 tumors obtained per group. The number of VEGF positive cells were divided by the total cell count \( \times 100\% \) under 400\( \times \) magnification. A medium or intense brown cytoplasmic staining was deemed as positive, while cells with unstained or light brown cytoplasmic staining were deemed as negative.

For \( \alpha \)-SMA expression analysis, we calculated as follows: five areas were selected randomly from each of the slides generated from the 6 tumors obtained per group. The number of \( \alpha \)-SMA positive profiles per mm\(^2\) of tumor sample was calculated under a 200\( \times \) magnification, as previously described.\(^{22}\)

**Oxygen microelectrode**

The partial pressure of oxygen (PO\(_2\)) in tumor tissue was determined by an oxygen microelectrode (Unisense A/S, Aarhus, Denmark). All operations were followed as described in the manufacturer’s instructions. Briefly, after the microelectrode was polarized and calibrated, anesthetized animals were placed in the prone position. Next, the microelectrode was insert into the tumor tissue vertically. The PO\(_2\) located at 1/2, 1/4, 1/8, and 1/16 short diameter of tumor tissue was calculated. The data obtained were then recorded using the data-acquisition software, SenseTrace Pro (Unisense A/S). In order to observe a variation in hypoxia, the PO\(_2\) of five animals from each group on the 5th, 10th, and 15th was measured.

![Figure 1 Treatment schedule.](https://www.dovepress.com/)

**Abbreviations:** Ip, intraperitoneal; ES, endostar; GEM, gemcitabine.
Micro 18F-FDG PET/CT imaging
The early tumor response in different groups was measured by an Inveon micro PET/CT animal scanner (Siemens, Munich, Germany). After the day of treatment ended, 3 mice from each group were fasted for 6–8 hrs, then anesthetized with 1% pentobarbital (5 mg/kg, IP) and injected intravenously (IV) with 2-deoxy-2-[fluorine-18] fluoro-D-glucose (18F-FDG) 100–200 micro curie (μCi). After 30 mins of 18F-FDG injection administration, treated mice were then fixed to the scanning frame in order to perform micro positron emission tomography integrated with computed tomography (PET/CT) imaging. The image plane of the largest tumor appearance was selected for data analysis. An irregular region of interest (ROI) containing the whole tumor was drawn manually. According to the ROI, the tracer uptake value in the tumor was defined in the attenuation-corrected transaxial tomographic slice by computing the standard uptake value. The maximal standardized uptake value (SUVmax) acquired from the selected ROI.

Statistical analyses
All data were expressed as the mean ± standard deviation (SD) and analyzed using the SPSS version 17.0 (IBM, Chicago, IL, USA). Statistical analysis was performed using the one-way ANOVA test. The Student-Newman-Keuls (SNK) method was used as a post-hoc test. P-value less than (<) 0.05 was considered to be statistically significant.

Results
Tumor volume
In our study, we evaluated the antitumor effects of Endostar in combination with gemcitabine on the growth of LLC tumors (Figure 2A) and we determined their optimal administration sequence in vivo using a mouse model. Drug treatments were initiated when the tumor volume diameter reached approximately 8–10 mm. At the end of the treatment (Figure 2A and C and Table 1), the tumors from the combination therapy, including GEM/ES (2284.83 mm3) and ES/GEM (2882.15 mm3), were significant smaller than ES alone (4386.95 mm3, P<0.05) or GEM alone (3452.79 mm3, P<0.05). The tumor volume was lowest in the ES + GEM group (1758.67 mm3) compared to all other treatment groups (P<0.05), whereas GEM alone group only modestly suppressed tumor growth compared to the control (4767.43 mm3, P<0.05). Consistent with the changes in tumor volume, the tumor weight (Figure 2B and Table 1) of the ES + GEM group (1.91 g) was significant lighter than the control (5.82 g, P<0.05), ES alone (5.14 g, P<0.05), GEM alone (4.37 g, P<0.05), ES/GEM (3.46 g, P<0.05), and GEM/ES (3.12 g, P<0.05).

Tumor oxygenation
Angiogenesis can induce tumor vasculature tends to be normal, thus hypoxia of tumor is improved. In our study, tumor oxygenation was calculated using an oxygen micro-electrode on day 5, 10, and 15 of treatment (Figure 3). As shown in Figure 3, the oxygenation levels of the ES alone group was significantly higher on day 5 (27.06 mmHg) and day 10 (23.46 mmHg) compared with the control.
group (18.26 mmHg, 15.58 mmHg, \(P<0.05\), while no obvious differences were observed between the ES alone (15.40 mmHg) and the control group (11.55 mmHg) on day 15 of treatment (\(P>0.05\)). Compared with all other groups, PO2 was highest in the ES + GEM group on day 5 (37.33 mmHg), day 10 (33.81 mmHg), and day 15 (27.35 mmHg) of treatment (\(P<0.05\)).

**Micro 18F-FDG PET/CT imaging**

The SUVmax values of 18F-FDG imaging for each group were (Figure 4): 4.2±0.4 for control, 3.83±0.26 for ES alone, 3.4±0.2 for GEM alone, 2.9±0.21 for ES/GEM, 2.3±0.21 for GEM/ES, and 1.73±0.12 for ES + GEM. The SUVmax values in the GEM alone group decreased

<table>
<thead>
<tr>
<th>Groups</th>
<th>Tumor volume (mm(^3))</th>
<th>Tumor weight (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>4767.43±986.57</td>
<td>5.82±0.99</td>
</tr>
<tr>
<td>ES alone</td>
<td>4386.95±732.88</td>
<td>5.14±0.82</td>
</tr>
<tr>
<td>GEM alone</td>
<td>3452.79±434.72</td>
<td>4.37±0.64</td>
</tr>
<tr>
<td>ES/GEM</td>
<td>2882.15±414.2</td>
<td>3.46±0.63</td>
</tr>
<tr>
<td>GEM/ES</td>
<td>2284.83±391.29</td>
<td>3.13±0.62</td>
</tr>
<tr>
<td>ES + GEM</td>
<td>1758.67±426.92</td>
<td>1.91±0.47</td>
</tr>
</tbody>
</table>

**Table 1** Tumor volume and tumor weight in LLC xenografted mice with various treatment regimens at the end of treatment.

Abbreviations: LLC, Lewis lung carcinoma; ES, Endostar; GEM, gemcitabine.

![Figure 3](image3.png) **Figure 3** Tumor oxygenation. The oxygenation levels in different groups on day5, day10, day15 after treatment. Results are expressed as mean ± SD. *\(P<0.05\) vs control group, **\(P<0.05\) vs all groups.

![Figure 4](image4.png) **Figure 4** Micro 18F-FDG PET/CT imaging. (A) Representative 18F-FDG PET scans of mice one day after treatment with various regimens. (B) SUVmax associated with various treatment regimens. *\(P<0.05\) vs control group, **\(P<0.05\) vs all groups.

**Abbreviations:** ES, endostar; GEM, gemcitabine.
considerably compared with the control ($P<0.05$). Among all treatment groups, tumor cells in the ES + GEM group had the lowest SUVmax value ($P<0.05$). Surprisingly, no significant differences in SUVmax were observed between the ES alone group and the control group ($P>0.05$).

**Tumor cell cycle analysis**

After treatment completion, the tumor cell cycle was evaluated by flow cytometry in each of the treatment groups (Figure 5). Following the GEM alone treatment, the proportion of cells in the synthesis (S) phase (26.3%), increased slightly compared to the control (21.64%, $P<0.05$). Whereas, compared to the control (35.63%) and GEM alone group (39.63%), the cell cycle distribution in the G0/G1 phase, dedicated to cell division preparation, was remarkably higher in the ES alone group (47.35%, $P<0.05$). In particular, the ES + GEM group had the highest G0/G1 phase (59.16%) and S (39.09%) phase fraction compared to the control ($P<0.01$).

**Immunohistochemistry**

The expression of VEGF was evaluated via immunohistochemistry in order to determine the impact of Endostar and gemcitabine treatments (Figure 6). Both the control group (91.35%) and the GEM alone group (87.99%) had a higher number of VEGF positive cells compared to the ES alone (69.38%, $P<0.05$), ES/GEM (51.93%, $P<0.05$), GEM/ES (45.38%, $P<0.05$), and the ES + GEM (27.18%, $P<0.05$).

Tumors cells that were treated with ES + GEM had the lowest VEGF expression observed in all groups ($P<0.05$).

Moreover, α-SMA staining was performed to reveal the extent of angiogenesis taking place after various treatments (Figure 7). Compared with the control group (4.17 vessels/mm$^2$), the number of α-SMA positive blood vessels increased significantly in the ES alone (6.83 vessels/mm$^2$, $P<0.05$), ES/GEM (8.67 vessels/mm$^2$, $P<0.05$) and GEM/ES group (8.5 vessels/mm$^2$, $P<0.05$). However, no obvious differences were found between the GEM alone (4.67 vessels/mm$^2$) and the control group ($P>0.05$). In addition, the number of α-SMA positive blood vessels in the ES + GEM group (10.33 vessels/mm$^2$) was the highest among all the groups ($P<0.05$).

**Discussion**

It is now well accepted that a network of blood vessels develops to supply nutrients and oxygen to facilitate tumor cell growth, invasion, and metastasis. Based on this concept, anti-angiogenic therapy is a crucial approach for efficient antitumor treatments. Consistently, a myriad of studies investigating novel anti-angiogenic therapies have erupted in the last years. Nevertheless, several studies have shown that monotherapy treatments geared toward the inhibition of angiogenesis have performed poorly on tumor inhibition.$^{23,24}$ Importantly, the therapeutic efficacy of anti-angiogenic approaches is limited because of their major role in

![Figure 5](https://example.com/figure5.png)

**Figure 5** Cell cycle analysis of tumor tissue from mice in different groups. (A) Flow cytometry analysis of cell cycle redistribution in xenografts from mice in different groups. (B) Percentage of cells in G0/G1, S, G2/M phase in mouse xenografts in different treatment groups. $^{*}P<0.05$ vs control group, $^{**}P<0.05$ vs all groups.

**Abbreviations:** ES, endostar; GEM, gemcitabine.
angiogenesis, as with tumor treatment with the VEGF-A inhibitor, bevacizumab (Avastin, Roche). When tumors possess abnormal vascular networks, tumor cells become less sensitive to chemotherapy. Despite these disadvantages, preclinical and clinical studies indicate that antiangiogenic therapy in combination with chemotherapy is more effective than single anti-angiogenic modalities in cancer treatments. In the present study, our data also confirm that a combination therapy has advantages as antitumor treatment, compared to monotherapies. However, despite these findings, the optimal administration schedule for a combination therapy consisting of...
anti-angiogenic agents and chemotherapy treatments has not been fully elucidated.

In agreement with previous studies, the present study demonstrates that Endostar monotherapy does not suppress tumor growth effectively, both in terms of tumor volume and tumor weight. In contrast, the combination therapy of Endostar and gemcitabine suppresses tumor growth in an appreciable manner relative to monotherapy treatment with either drug. The positive effect of this treatment was also assessed using 18F-FDG PET/CT imaging. 18F-FDG, an analogue of glucose, is widely used as a functional molecular biomarker for PET imaging, as it allows for the visualization for glucose metabolism. It is now well known that many biological activities require energy, which is essential for proper cell metabolism. Unlike normal cells, the majority of the energy used by tumor cells relies on glycolysis, mediated by glycometabolic pathways, and not by aerobic oxidation. Thus, inhibiting proliferation can weaken glycometabolism. Importantly, higher FDG uptake reflect rapid glucose metabolism, whereas poor FDG uptake implies a reduction in glucose metabolism. Thus, the use of the radiotracer 18F-FDG PET/CT is an important approach to predict tumor malignancy in a clinical setting. Our data suggest that combination therapy leads to slower FDG uptake compared to Endostar monotherapy, indicating that Endostar combined with chemotherapy treatment can enhance its antitumor effect. In addition, H&E staining of the heart, liver, spleen, lung, and kidney from each of the treatment groups was evaluated microscopically (Figure 8). Notably, no significant morphological changes in these organs were found, which indicates that the combination therapy used did not have obvious adverse impacts on normal tissues.

This phenomenon of augmented antitumor effect under a combination therapy of Endostar with chemotherapy is associated with changes in tumor vascular normalization. As previously described, antiangiogenic treatments have been shown to result in tumor vascular functional and structural normalization. Thus, the normal basement membrane increases, such as pericytes, which enhances drug delivery into tumors. Pericytes as a key characteristic of mature microvessels, such as making contact of endothelial closer and enhancing the stability of vessels. Pericytes were assessed using α-SMA, a maker for the maturity and function of blood vessels. The present study demonstrates that the combination of Endostar and gemcitabine result in higher number of pericytes compared to the control or gemcitabine only treatment groups. These results indicate that Endostar treatment led to higher number of mature blood vessels, as well as enhanced drug delivery into tumors.

**Figure 8** Organs morphology of mice from different groups. Hematoxylin-eosin staining of the heart, liver, spleen, lung, kidney in different groups. (A) Control group, (B) ES alone group, (C) GEM alone group, (D) ES/GEM group, (E) GEM/ES group, and (F) ES + GEM group.

**Abbreviations:** ES, endostar; GEM, gemcitabine.
vessels and normalized function of the tumor vasculature. Therefore, the antitumor effects were enhanced compared to a single agent therapy. Hypoxia is common in solid tumors and influences the sensitivity of tumors to radiotherapy and chemotherapy. A previous study found that hypoxia improves after antiangiogenesis therapy. In our study, Endostar alone and the three combined treatments all induced a higher oxygen partial pressure on days 5 and 10 of the treatment, suggesting that Endostar improved hypoxia and increased the antitumor efficiency of chemotherapy.

Peng et al found that the therapeutic effect improved after radiotherapy treatments were delivered following Endostar administration for 5–7 days in xenografts of the human nasopharyngeal carcinoma (NPC) cell line CNE-2 (CNE-2 NPC) or following Endostar administration for 3–5 days in 5-8F NPC xenografts. On the contrary, we found that tumor volume was the lowest and had the slowest FDG uptake in the ES + GEM group after 15 days of treatment. These results suggest that administration of Endostar with gemcitabine simultaneously, is the optimal combination therapy, compared to successive administration. In addition, according to Huang et al treatment with the chemotherapy agent paclitaxel followed by Endostar treatment may also induce a synergistic effect when compared to treatment of each drug alone. However, in our study, the antitumor effect observed in the ES + GEM group was more powerful than the effect seen with the ES/GEM or GEM/ES groups. We hypothesize that this phenomenon may be due to a modulation of the VEGF pathway.

VEGF signals play a vital role in angiogenesis. Several studies have suggested that the expression of VEGF is enhanced after chemotherapy treatments. It has also been reported that chemotherapy drugs may inhibit VEGF expression, and these drugs may also induce angiogenesis. Endostar is an antiangiogenic agent, but its mechanism of action is still not fully understood. Moreover, gemcitabine could inhibit VEGF expression early in treatment but increase VEGF expression with long-term treatment. In our study, the GEM alone treatment showed no obvious influence on VEGF expression relative to the control group at the end of the treatment. Interestingly, gemcitabine administration with Endostar simultaneously decrease the expression of VEGF significantly. This indicates that Endostar has the potential to downregulate VEGF expression, consistent with previous studies by Li et al. Furthermore, VEGF inhibition was enhanced when Endostar was administered with gemcitabine simultaneously.

Gemcitabine, as a cytotoxic drug, acts mainly on tumor cells in the S phase. In the present study, we also observed a cell cycle arrest in the S phase with the gemcitabine treatment. Therefore, the cell cycle was blocked and tumor cells were not able to complete proliferation. Interestingly, our study demonstrates that there was more cells in the G0/G1 phase Endostar treatment and that Endostar may influence cell cycle distribution. This finding has also been reported by Xu and colleagues. When exposed to a combination of Endostar and gemcitabine simultaneously, the proportions of cells in the G0/G1 and S phases both increased sharply. Our data suggest that simultaneous treatment of Endostar and gemcitabine regulate the cell cycle in different phases, thereby generating an additive effect. Additionally, it indicates that gemcitabine might also induce cell cycle arrest in the G0/G1 phase under conditions involving the simultaneous administration of these two agents.

In conclusion, our study demonstrates that the simultaneous treatment of Endostar and gemcitabine exerts synergistic effects as antitumor therapy. Nevertheless, our data does not confirm an optimal time window for the treatment of Endostar in combination with gemcitabine. Du et al have reported that a lower dose of Endostar (10 mg/kg) in combination with cisplatin, administered simultaneously, can have a synergistic effect than each therapy alone, while in a study published by Li et al, an observed synergistic therapeutic effect was seen with a dose of 20 mg/kg of Endostar followed by cisplatin treatment. Thus, we hypothesize that this time window may be associated with the dosage of Endostar. Further studies are needed to explore the optimal time windows associated with different doses of Endostar alone and in combination with other antitumor agents. In addition, the positive effects of these chemotherapy combinations, as well as the subset of patients that may benefit the most from these treatments.

Acknowledgments
The author would like to thank the members of the department of Pathology and Nuclear medicine, oncology laboratory of Affiliated Hospital of Southwest Medical University for providing assistance throughout the duration of the study. All authors declare that they have no competing interests.
Disclosures

The authors report no conflicts of interest in this work.

References


